Southwest Pharmaceutical Co., Ltd.

Not yet clear

This product belongs to the class Ic (i.e., directly acting on the cell membrane) antiarrhythmic drug. The experimental results of isolated animal myocardium indicate that 0.5-1ug/min can reduce the depolarization effect during contraction, thereby prolonging conduction, slightly prolonging the duration of action potential and the effective refractory period, and can increase the threshold potential of myocardial cells, significantly reducing the spontaneous excitability of the myocardium. It acts on both the atrium and ventricle (mainly affecting the Purkinje fibers, with a smaller effect on the myocardium), and also on the formation and conduction of excitement. Clinical data show that the therapeutic dose (300mg orally and 30mg intravenously) can reduce the irritability of the myocardium, the effect is long-lasting, PQ and QRS are increased, and the effective refractory period of the atrium and atrioventricular node is prolonged. It has an antagonistic effect on various types of experimental arrhythmias.

1. It is a Class Ic antiarrhythmic drug that can reduce the depolarization effect during contraction, prolong conduction, slightly prolong the duration of action potential and the effective refractory period, and increase the threshold potential of myocardial cells, reducing the spontaneous excitability of the myocardium; 2. It can reduce myocardial irritability at therapeutic doses, prolong the effective refractory period of the atria and atrioventricular nodes, and combat various types of experimental arrhythmias; 3. The antiarrhythmic effect is related to its membrane stabilizing effect and competitive β-blocking effect, and it also has a weak calcium antagonist effect and a mild myocardial inhibitory effect; 4. It can relax the coronary artery and bronchial smooth muscle; 5. It has a local anesthetic effect similar to procaine.